Ibrutinib Archives - Medical Conferences

CAPTIVATE: Ibrutinib plus venetoclax shows ongoing efficacy in CLL

Presented By

Dr Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Trial

Phase 2, CAPTIVATE

Conference

ASH 2021

4 February, 2022 11:41

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert

Dr Jennifer Woyach, Ohio State University, OH, USA

Trial

Phase 3, Alliance A041202

Conference

ASH 2021

3 February, 2022 23:22

Afbeelding met persoon, person Automatisch gegenereerde beschrijving

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Expert

Dr. Talha Munir, Leeds Teaching Hospitals NHS Trust, UK

Trial

Phase 3, GLOW

Conference

ASH 2021

3 February, 2022 23:15

CAPTIVATE: Ibrutinib plus venetoclax show stunning efficacy in CLL

Expert

Prof. Paolo Ghia, Università Vita-Salute San Raffaele, Italy

Trial

Phase 2, CAPTIVATE

Conference

ASH 2021

20 January, 2022 16:29

Acalabrutinib as effective but better tolerated than ibrutinib in CLL

Presented By

Prof. John Byrd, Ohio State University Comprehensive Cancer Center, OH, USA

Trial

Phase 3, ELEVATE-RR

Conference

ASCO 2021

12 August, 2021 13:22

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By

Dr Laurie Sehn, University of British Columbia, Vancouver, Canada

Trial

Phase 3, ESCALADE

Journal

Physician's Weekly

Conference

ASCO 2021

6 August, 2021 12:36

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety compared with ibrutinib

Presented By

Dr. John Byrd , Ohio State University College of Medicine, USA

Trial

Phase 3, ELEVATE-RR

Journal

Physician's Weekly

Conference

ASCO 2021

6 August, 2021 11:55

Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL

Presented By

Prof. Peter Hillmen, University of Leeds, UK

Trial

Phase 3, ALPINE

Conference

EHA 2021

5 August, 2021 14:08

ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib

Presented By

Prof. Peter Hillmen, St James’s University Hospital, UK

Trial

Phase 3, ELEVATE-RR

Conference

EHA 2021

5 August, 2021 13:43

GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment

Presented By

Prof. Arnon Kater, Amsterdam University Medical Centres, the Netherlands

Trial

Phase 2, GLOW

Conference

EHA 2021

5 August, 2021 13:33

PFS and ORR benefits of first-line ibrutinib-based treatment in CLL

Presented By

Prof. Jan Burger, MD Anderson Cancer Center, Texas, USA

Trial

Phase 3, RESONATE-2, iLLUMINATE

Conference

ASH 2020

18 February, 2021 08:54

Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia

Presented By

Prof. Meletios Dimopoulos, University of Athens, Greece

Trial

Phase 3, ASPEN

Conference

EHA 2020

9 September, 2020 12:10

Exciting survival data for ibrutinib vs placebo in treatment-naïve, early-stage CLL

Presented By

Dr Petra Langerbeins, University of Cologne, Germany

Trial

Phase 3, CLL12

Conference

EHA 2019

9 August, 2019 16:26